Literature DB >> 10409677

Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1.

T Makinen1, B Olofsson, T Karpanen, U Hellman, S Soker, M Klagsbrun, U Eriksson, K Alitalo.   

Abstract

Vascular endothelial growth factor B (VEGF-B) is expressed in various tissues, especially strongly in the heart, and binds selectively to one of the VEGF receptors, VEGFR-1. The two splice isoforms, VEGF-B(167) and VEGF-B(186), have identical NH(2)-terminal cystine knot growth factor domains but differ in their COOH-terminal domains which give these forms their distinct biochemical properties. In this study, we show that both splice isoforms of VEGF-B bind specifically to Neuropilin-1 (NRP1), a receptor for collapsins/semaphorins and for the VEGF(165) isoform. The NRP1 binding of VEGF-B could be competed by an excess of VEGF(165). The binding of VEGF-B(167) was mediated by the heparin binding domain, whereas the binding of VEGF-B(186) to NRP1 was regulated by exposure of a short COOH-terminal proline-rich peptide upon its proteolytic processing. In immunohistochemistry, NRP1 distribution was found to be overlapping or adjacent to known sites of VEGF-B expression in several tissues, in particular in the developing heart, suggesting the involvement of VEGF-B in NRP1-mediated signaling.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10409677     DOI: 10.1074/jbc.274.30.21217

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  VEGF-B: a thing of beauty.

Authors:  Xuri Li
Journal:  Cell Res       Date:  2010-06-08       Impact factor: 25.617

Review 2.  Semaphorins in angiogenesis and tumor progression.

Authors:  Gera Neufeld; Adi D Sabag; Noa Rabinovicz; Ofra Kessler
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

3.  VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis.

Authors:  Fan Zhang; Zhongshu Tang; Xu Hou; Johan Lennartsson; Yang Li; Alexander W Koch; Pierre Scotney; Chunsik Lee; Pachiappan Arjunan; Lijin Dong; Anil Kumar; Tuomas T Rissanen; Bin Wang; Nobuo Nagai; Pierre Fons; Robert Fariss; Yongqing Zhang; Eric Wawrousek; Ginger Tansey; James Raber; Guo-Hua Fong; Hao Ding; David A Greenberg; Kevin G Becker; Jean-Marc Herbert; Andrew Nash; Seppo Yla-Herttuala; Yihai Cao; Ryan J Watts; Xuri Li
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-06       Impact factor: 11.205

4.  Purification and refolding of vascular endothelial growth factor-B.

Authors:  S D Scrofani; L J Fabri; P Xu; P Maccarone; A D Nash
Journal:  Protein Sci       Date:  2000-10       Impact factor: 6.725

Review 5.  Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.

Authors:  Eva Bandrés; Ruth Zárate; Natalia Ramirez; Ana Abajo; Nerea Bitarte; Jesus Garíia-Foncillas
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

6.  Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding.

Authors:  Brent A Appleton; Ping Wu; Janice Maloney; JianPing Yin; Wei-Ching Liang; Scott Stawicki; Kyle Mortara; Krista K Bowman; J Michael Elliott; William Desmarais; J Fernando Bazan; Anil Bagri; Marc Tessier-Lavigne; Alexander W Koch; Yan Wu; Ryan J Watts; Christian Wiesmann
Journal:  EMBO J       Date:  2007-11-08       Impact factor: 11.598

Review 7.  Endothelial fatty acid transport: role of vascular endothelial growth factor B.

Authors:  Carolina Hagberg; Annika Mehlem; Annelie Falkevall; Lars Muhl; Ulf Eriksson
Journal:  Physiology (Bethesda)       Date:  2013-03

8.  Structural insights into the binding of vascular endothelial growth factor-B by VEGFR-1(D2): recognition and specificity.

Authors:  Shalini Iyer; Paula I Darley; K Ravi Acharya
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

9.  Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis.

Authors:  Imke Albrecht; Lucie Kopfstein; Karin Strittmatter; Tibor Schomber; Annelie Falkevall; Carolina E Hagberg; Pascal Lorentz; Michael Jeltsch; Kari Alitalo; Ulf Eriksson; Gerhard Christofori; Kristian Pietras
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

10.  Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect.

Authors:  Emely Castro-Rivera; Sophia Ran; Philip Thorpe; John D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.